Edwards Lifesciences Corp
Change company Symbol lookup
Select an option...
EW Edwards Lifesciences Corp
COP ConocoPhillips
FBP First Bancorp
PTCT PTC Therapeutics Inc
ROKU Roku Inc
WORK Slack Technologies Inc
ARKW ARK Next Generation Internet ETF
SPOT Spotify Technology SA
GBTC Grayscale Bitcoin Trust (BTC)
ARKK ARK Innovation ETF

Health Care : Health Care Equipment & Supplies | Large Cap Growth
Company profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.

Closing Price
Day's Change
0.38 (0.43%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Square stock gets an upgrade as analyst says not to 'overlook' Cash App potential

5:44 pm ET November 9, 2020 (MarketWatch)

By Emily Bary

BTIG likes that Square is getting more small businesses to use the traditionally consumer-focused Cash App -- for a fee

Square Inc. seems to be cooking in all aspects of its business, and that earned its stock an upgrade late Monday.

BTIG analyst Mark Palmer raised his rating on Square's stock (SQ) to buy from neutral, writing that the company's latest earnings report (https://www.marketwatch.com/story/square-stock-rockets-after-earnings-beat-11604612690) showed a perfect combination of continued momentum (https://www.marketwatch.com/story/square-stock-heads-for-record-close-as-earnings-show-opportunity-is-too-big-to-ignore-11604680388) with the consumer-facing Cash App and an unexpectedly quick recovery for the merchant-focused Seller business.

Shares of Square were up 0.7% in after-hours trading Monday after dropping more than 7% in the regular session. While shares of other payments names including Visa Inc. (V) and Mastercard Inc. (MA)rocketed in Monday trading (https://www.marketwatch.com/story/visa-mastercard-american-express-stocks-surge-on-hopes-for-travel-recovery-amid-upbeat-vaccine-news-11604948127) upon upbeat vaccine news (https://www.marketwatch.com/story/biontech-and-pfizer-say-their-covid-19-vaccine-candidate-is-90-effective-2020-11-09?mod=home-page) from Pfizer Inc. (PFE) and BioNTech SE (BNTX), those stocks hadn't done much over the course of the pandemic, whereas Square's had more than doubled.

BTIG's Palmer wrote that he was "not overlooking" the potential for tough comparisons starting in the second half of 2021, "nor are we unaware of the perception that its valuation is stretched." Still, he remains upbeat about Square's ability to make inroads in its two main markets. The Seller business represents a $100 billion-plus market opportunity, he wrote, while the Cash App sits on a $60 billion-plus opportunity.

"We believe investors in grasping the extent to which the pandemic had been a game-changer with regard to the growth trajectory of Square's Cash App should not overlook the extent of the progress made by its Cash App for Business product, which enables small businesses to accept payments from consumers using Cash App for which they pay the company a fee," Palmer wrote. He notes that this business generated $2.9 billion in gross payment volume during the third quarter, up 322% from a year earlier and enough to account for 9% of Square's consolidated gross payment volume.

In addition, Palmer said that Square "meaningfully broadened its potential user base" by allowing stock-trading on the Cash App and positioned itself to become "an even more widely accepted means of accelerating the receipt of government transfer payments" through its work in facilitating stimulus disbursements through the app.

Palmer had prior concerns about Square's lending business, which he worried could make the company "increasingly dependent on the extension of credit to small- and medium-sized businesses as a means of driving sales in its core payments business." He argued that Square may have changed its approach to credit extension during the initial months of the pandemic, as it paused the Square Capital unit's new flex loan offering until he end of July.

Read: Visa and Mastercard have a lot in common, but COVID-19 puts one key difference in focus (https://www.marketwatch.com/story/visa-and-mastercard-have-a-lot-in-common-but-covid-19-puts-one-key-difference-in-focus-11604090026)

"While Square management appeared to embrace lending as a new avenue for growth at a time when questions lingered about its growth trajectory, we believe the advent of Cash App as a potential 'super app' has negated the need for it to lean on Square Capital," Palmer wrote. Financial technology apps in China like Alipay are sometimes referred to as "super-apps" because they combine many money-related services in one place.

Palmer set a $220 price target on Square's stock, which has gained 194% so far this year as the S&P 500 has risen 10%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 09, 2020 17:44 ET (22:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.